Civic Intelligence

Path Vaccine Solutions

990 • Fiscal year 2012 • EIN 83-0431851

Jan 01, 2012 to Dec 31, 2012

Seattle, WA
Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

10th percentile

0.02x

Higher debt load relative to assets than 10% of similar nonprofits.

2012 filings • 501(c)3 • $100M-$250M nonprofits • Source year 2012

Liabilities / Revenue

11th percentile

0.05x

Higher debt load relative to revenue than 11% of similar nonprofits.

2012 filings • 501(c)3 • $100M-$250M nonprofits • Source year 2012

Net Margin

82nd percentile

23%

Higher net margin than 82% of similar nonprofits.

2012 filings • 501(c)3 • $100M-$250M nonprofits • Source year 2012

Top Officer Pay

Score unavailable

No value available

This filing does not contain officer compensation rows.

Source year 2012

Asset Growth

65th percentile

6.4%

Faster asset growth than 65% of similar nonprofits.

2012 filings • 501(c)3 • $100M-$250M nonprofits • Annualized from 2011 to 2012

Revenue Growth

96th percentile

187%

Faster revenue growth than 96% of similar nonprofits.

2012 filings • 501(c)3 • $100M-$250M nonprofits • Annualized from 2011 to 2012

Assets

Up

$142,045,531

Up $8,537,550 (+6.4%) from 2011

Net Assets

Up

$139,194,788

Up $12,378,026 (+9.8%) from 2011

Liabilities

Down

$2,850,743

Down $3,840,476 (-57%) from 2011

Revenue

Up

$52,130,143

Up $33,948,606 (+187%) from 2011

Expenses

Up

$40,164,028

Up $2,937,463 (+7.9%) from 2011

Net Income

Up

$11,966,115

Up $31,011,143 (+163%) from 2011

Historical Trend

Balance Sheet Trend

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$200M$150M$100M$50M$0Assets 2010: $151,102,797Liabilities 2010: $4,781,234Net Assets 2010: $146,321,5632010Assets 2011: $133,507,981Liabilities 2011: $6,691,219Net Assets 2011: $126,816,7622011Assets 2012: $142,045,531Liabilities 2012: $2,850,743Net Assets 2012: $139,194,7882012Assets 2013: $166,859,076Liabilities 2013: $6,024,155Net Assets 2013: $160,834,9212013Assets 2014: $149,044,550Liabilities 2014: $10,278,308Net Assets 2014: $138,766,2422014Assets 2015: $150,830,465Liabilities 2015: $4,059,847Net Assets 2015: $146,770,6182015Assets 2016: $107,465,507Liabilities 2016: $15,803,401Net Assets 2016: $91,662,1062016Assets 2017: $66,391,789Liabilities 2017: $14,042,965Net Assets 2017: $52,348,8242017Assets 2018: $38,472,788Liabilities 2018: $37,875,254Net Assets 2018: $597,5342018Assets 2019: $38,989,543Liabilities 2019: $36,842,677Net Assets 2019: $2,146,8662019

Highlighted filing

2012

Assets$142,045,531
Liabilities$2,850,743
Net Assets$139,194,788

Operations Trend

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$100M$50M$0-$50MExpenses 2010: $35,920,9952010Revenue 2011: $18,181,537Expenses 2011: $37,226,565Net Income 2011: -$19,045,0282011Revenue 2012: $52,130,143Expenses 2012: $40,164,028Net Income 2012: $11,966,1152012Revenue 2013: $59,399,215Expenses 2013: $37,490,390Net Income 2013: $21,908,8252013Revenue 2014: $24,771,754Expenses 2014: $47,169,027Net Income 2014: -$22,397,2732014Revenue 2015: $46,734,872Expenses 2015: $38,397,069Net Income 2015: $8,337,8032015Revenue 2016: $5,990,503Expenses 2016: $42,072,773Net Income 2016: -$36,082,2702016Revenue 2017: $7,108,916Expenses 2017: $43,734,346Net Income 2017: -$36,625,4302017Revenue 2018: $35,807,318Expenses 2018: $35,391,575Net Income 2018: $415,7432018Revenue 2019: $10,961,263Expenses 2019: $9,746,391Net Income 2019: $1,214,8722019

Highlighted filing

2012

Revenue$52,130,143
Expenses$40,164,028
Net Income$11,966,115
Filing Detail Status

This 2012 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.

Jump To
Filing Snapshot
Filing Period
Jan 1, 2012 to Dec 31, 2012
Mission and Program Overview

Mission

The mission of path vaccine solutions (pvs) is to improve the health of children in low-income countries by accelerating the development of vaccines that will be effective and affordable for those who need them most. From initial discovery through clinical trials, pvs works with commercial partners, such as vaccine manufacturers and biotechnology firms, and nonprofit partners, such as universities and research institutions, to shorten the timeline for vaccine development.pvs works with partners to develop new vaccines by providing funding and expertise in preclinical development, manufacturing, and clinical development, with a focus on low-resource countries. In return, partners agree to terms that help ensure the resulting products are affordable and available in developing countries.

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings